Sunshine Biopharma Gains Health Canada Approval for Generic Amoxicillin, Shipments in August 2026
Sunshine Biopharma receives Health Canada approval for its generic Amoxicillin, expected to ship to pharmacies in August 2026 across multiple dosage forms. The global Amoxicillin market was estimated at $4.9B–$5.9B in 2025, with Canada representing roughly 2% and providing Sunshine Biopharma potential revenue growth from its 60-entry generic portfolio.
1. Canadian Regulatory Approval
Sunshine Biopharma has obtained approval from Health Canada for its generic Amoxicillin formulation, covering multiple dosage forms and strengths. The product is anticipated to be ready for shipment to Canadian pharmacies in August 2026.
2. Market Potential
Global Amoxicillin sales revenue reached an estimated $4.9B–$5.9B in 2025, growing at a 2.9% CAGR to 2031. With Canada comprising approximately 2% of this market, the approval offers Sunshine Biopharma an incremental revenue opportunity of around $100M annually.
3. Strategic Portfolio Expansion
This approval increases Sunshine Biopharma’s Canadian portfolio to 61 generic prescription drugs. The company plans to launch 12 additional generics by the end of 2026, reinforcing its strategy to provide affordable, high-quality antibiotics and drive midterm revenue growth.